154 completed, 56 unknown, 35 recruiting, 30 not yet recruiting. 89 Not applicable, 55 Phase 3, 35 Phase 4, 29 Phase 2, 8 Phase 1.
Follow Community-Acquired Pneumonia: new trials by email Literature Review of Community-Acquired Pneumonia trials Research Report on Community-Acquired Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily - Community Acquired Pneumonia (CAP) | Phase 4 | Not yet recruiting | University of Maryland, Baltimore | 900 | 2027-02-01 | 2026-11-05 |
| Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections PRACTICE-LRTI multimodal antimicrobial stewardship programme - Bronchitis, Acute, Community-acquired Pneumonia | Not applicable | Not yet recruiting | Tampere University | 50000 | 2027-01-01 | 2026-11-03 |
| Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia Multi Drug Resistant Infections, Pneumnia | Not yet recruiting | Henan University of Traditional Chinese Medicine | 652 | 2026-12-01 | 2026-10-30 | |
| FIA Acute Inflammation ⁵⁷Fe-labelled ferrous sulphate, ⁵⁸Fe-citrate - Inflammation, Iron Absorption | Not applicable | Not yet recruiting | University of Zurich | 48 | 2026-11-09 | 2026-11-12 |
| Antibiotic Therapy In Respiratory Tract Infections Predetermined treatment duration, Variable treatment duration - Community-Acquired Pneumonia | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 310 | 2026-11-01 | 2026-11-12 |
| Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia Inhaled levofloxacin, Standard-of-care / Usual care - Community-acquired Pneumonia, CAP | Phase 2 / Phase 3 | Active not recruiting | Copenhagen Respiratory Research | 460 | 2026-10-08 | 2026-11-05 |
| CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL Placebo, clarithromycin - Sepsis | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 252 | 2026-09-16 | 2026-11-03 |
| TCM Cohort for Elderly CAP Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM) - Community-acquired Pneumonia (CAP) | Not yet recruiting | Henan University of Traditional Chinese Medicine | 2234 | 2026-08-20 | 2026-09-01 | |
| Lefamulin Post-Market Surveillance Study This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted. - Community-Acquired Pneumonia (CAP) | Recruiting | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 1000 | 2026-06-30 | 2026-08-07 | |
| 3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT Amoxicillin - Community Acquired Pneumonia, Childhood Pneumonia | Early Phase 1 | Not yet recruiting | Khyber Teaching Hospital | 250 | 2026-06-01 | 2026-06-15 |
| Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia NRICM102, Placebo, Intravenous Antibiotic - Mild to Moderate, Community-Acquired Pneumonia (CAP) | Phase 2 | Not yet recruiting | National Research Institute of Chinese Medicine, Ministry of Health and Welfare | 150 | 2026-06-01 | 2026-05-13 |
| Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds Multimodal respiratory data collection - Asthma (Diagnosis), Community-Acquired Pneumonia (CAP) | Not yet recruiting | Shanghai Children's Medical Center | 1400 | 2026-06-01 | 2026-05-29 | |
| Community-acquired Pneumonia Due to Chlamydia Pneumoniae Community-Acquired Pneumonia | Not yet recruiting | Centre Hospitalier de Saint-Denis | 200 | 2026-06-01 | 2026-07-01 | |
| PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms The novel care pathway intervention, Usual Care Alone - Community-Acquired Pneumonia (CAP), Pneumonia | Not applicable | Recruiting | Jeffrey Pernica | 698 | 2026-04-15 | 2026-04-29 |
| Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia Nogapendekin alfa inbakicept (NAI), agenT-797 - Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Effect of tNGS on CAP Patients With Initial Treatment Failure Targeted next-generation sequencing, Conventional microbiological testing, Follow-up at Day 30 - Community Acquired Pneumonia (CAP) | Not applicable | Not yet recruiting | Capital Medical University | 524 | 2026-04-10 | 2026-03-16 |
| Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP) | Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 168 | 2026-04-08 | 2026-05-11 |
| Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP) Methylprednisolone (drug), hydrocortisone - Community Acquired Pneumonia (CAP) | Phase 4 | Recruiting | Copenhagen Respiratory Research | 1600 | 2026-03-10 | 2026-03-18 |
| Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia Methylprednisolone - Acute Respiratory Failure, Community-Acquired Pneumonia | Phase 1 / Phase 2 | Not yet recruiting | Qingyuan Zhan | 500 | 2026-02-01 | 2026-01-22 |
Showing 20 of 324. Sign in to see all of them.
Pneumonia (94) · Pneumonia, Bacterial (20) · Healthcare-Associated Pneumonia (19) · Respiratory Tract Infections (16) · Sepsis (16) · COVID-19 (11) · Bronchitis (9) · Pulmonary Disease, Chronic Obstructive (9) · Respiratory Distress Syndrome (9) · Infections (8) · Community-Acquired Infections (7) · Emergencies (6) · Influenza, Human (6) · Pneumonia, Ventilator-Associated (6)
Respiratory Tract Diseases (320) · Community-Acquired Infections (317) · Infections (316) · Respiratory Tract Infections (308) · Pneumonia (230) · Lung Diseases (141) · Pathological Conditions, Signs and Symptoms (75) · Pathologic Processes (70) · Disease Attributes (44) · Bacterial Infections and Mycoses (43) · Bacterial Infections (36) · Virus Diseases (23) · Inflammation (22) · Iatrogenic Disease (20) · Cross Infection (18)
Levofloxacin (16) · Ceftriaxone (13) · Amoxicillin (12) · Amoxicillin-Potassium Clavulanate Combination (12) · Moxifloxacin (12) · Azithromycin (10) · Sodium Chloride (8) · Clarithromycin (7) · Methylprednisolone (7) · Ceftaroline (6) · Blood Specimen Collection (5) · Injections (4) · Saline Solution (4) · nemonoxacin (4) · Adrenal Cortex Hormones (3)
Pfizer (13) · Assistance Publique - Hôpitaux de Paris (6) · Capital Medical University (6) · Qingyuan Zhan (6) · Assiut University (5) · Bayer (5) · Hellenic Institute for the Study of Sepsis (5) · UMC Utrecht (5) · Biotest (4) · Forest Laboratories (4) · Henan University of Traditional Chinese Medicine (4) · Nordsjaellands Hospital (4) · TaiGen Biotechnology Co., Ltd. (4) · University Hospital, Basel, Switzerland (4) · University of Milan (4)
United States (52) · France (40) · Spain (32) · China (29) · Germany (23) · Italy (17) · Denmark (16) · Netherlands (16) · Canada (15) · Russia (15) · Brazil (14) · Switzerland (14) · Argentina (13) · Greece (13) · Hungary (11)
Adam Hloska, M.D. (2) · Bin Cao, MD (2) · Birgitte Lindegaard, MD, PhD (2) · Christian Backer Mogensen (2) · Francesco Violi, MD (2) · Giulio DiDiodato, MD (2) · Grit Barten-Neiner (2) · Jeffrey Pernica, MD (2) · Jiansheng Li, Doctor (2) · Luis Felipe Reyes, MD, MSc, PhD (2) · Roberto Cangemi (2)
PMID 12955634, PMID 21482570, PMID 23357290, PMID 23578215, PMID 24106842, PMID 24551881, PMID 25487791, PMID 26702925, PMID 30597021, PMID 32919458, PMID 33394942, PMID 33395094, PMID 33964925, PMID 34473343, PMID 34922058, PMID 37489818, PMID 11434826, PMID 11785851, PMID 12038946, PMID 12039881, PMID 12955635, PMID 14625336, PMID 15293621, PMID 15546111, PMID 15555836, PMID 15561835, PMID 15993671, PMID 16236878, PMID 16603606, PMID 16669925, PMID 16763247, PMID 17090560, PMID 17278083, PMID 17765048, PMID 17766633, PMID 17901791, PMID 18096708, PMID 18245147, PMID 18328306, PMID 18419482, PMID 18490403, PMID 18508226, PMID 18566081, PMID 18990531, PMID 19738090, PMID 19783532, PMID 19846634, PMID 20097417, PMID 20154071, PMID 20370777
2019 (4), 2023 (4), 2015 (2), 2018 (2), 2009 (1), 2014 (1), 2025 (1), R01GM101197 (1), R61HL183016 (1), U01AI066569 (1)